Protagonist Therapeutics
PTGX
PTGX
139 hedge funds and large institutions have $1.19B invested in Protagonist Therapeutics in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 54 increasing their positions, 47 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
29% less capital invested
Capital invested by funds: $1.67B → $1.19B (-$486M)
31% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 29
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
Holders
139
Holding in Top 10
4
Calls
$52.9M
Puts
$14.7M
Top Buyers
| 1 | +$52M | |
| 2 | +$29.1M | |
| 3 | +$17M | |
| 4 |
State Street
Boston,
Massachusetts
|
+$16.2M |
| 5 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$13M |
Top Sellers
| 1 | -$53.5M | |
| 2 | -$40.1M | |
| 3 | -$18.5M | |
| 4 |
SC
Samlyn Capital
New York
|
-$15.4M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$14.8M |